| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/BF03345499 |
| P698 | PubMed publication ID | 12109628 |
| P2093 | author name string | Tassone F | |
| Giordano R | |||
| Ghigo E | |||
| Grottoli S | |||
| Maccario M | |||
| Gauna C | |||
| Rossetto R | |||
| Maccagno B | |||
| P2860 | cites work | Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man. | Q30449288 |
| The Central Melanocortin System and Energy Homeostasis | Q33687989 | ||
| Regulation of growth hormone secretion by signals produced by the adipose tissue. | Q33708529 | ||
| Neuroendocrine regulation and actions of leptin | Q33777677 | ||
| Ghrelin: discovery of the natural endogenous ligand for the growth hormone secretagogue receptor | Q33942714 | ||
| Biologic activities of growth hormone secretagogues in humans | Q34231668 | ||
| Adrenal responsiveness to high, low and very low ACTH 1-24 doses in obesity | Q38307987 | ||
| GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism | Q38337944 | ||
| Effects of acipimox, an antilipolytic drug, on the growth hormone (GH) response to GH-releasing hormone alone or combined with arginine in obesity | Q38361307 | ||
| Endocrine function in human obesity | Q40259582 | ||
| Antidiabetic sulfonylurea enhances secretagogue-induced adrenocorticotropin secretion and proopiomelanocortin gene expression in vitro | Q40857936 | ||
| Dose-response aspects in the clinical assessment of the hypothalamo-pituitary-adrenal axis, and the low-dose adrenocorticotropin test | Q41079484 | ||
| Glucagon stimulates GH secretion after intramuscular but not intravenous administration. Evidence against the assumption that glucagon per se has a GH-releasing activity | Q42485626 | ||
| Regulation of pituitary-adrenocortical activity by free fatty acids in vivo and in vitro | Q42486778 | ||
| Metabolic modulation of the growth hormone-releasing activity of hexarelin in man. | Q42489063 | ||
| Effects of insulin on rat anterior pituitary cells. Inhibition of growth hormone secretion and mRNA levels | Q42511038 | ||
| In obesity the somatotrope response to either growth hormone-releasing hormone or arginine is inhibited by somatostatin or pirenzepine but not by glucose | Q42512966 | ||
| Growth-hormone release by glucagon | Q43726035 | ||
| A preview of growth hormone stimulation tests in children | Q44007797 | ||
| Suppression of counterregulatory hormone response to hypoglycemia by insulin per se. | Q44831762 | ||
| Evidence for a direct pituitary inhibition by free fatty acids of in vivo growth hormone responses to growth hormone-releasing hormone in the rat. | Q45127749 | ||
| The hypothalamic-pituitary-adrenal axis in obese women with different patterns of body fat distribution | Q48236785 | ||
| Subcutaneous glucagon as a test of the ability of the pituitary to secrete GH and ACTH. | Q48568565 | ||
| A comparison of the insulin tolerance/glucagon test with the short ACTH stimulation test in the assessment of the hypothalamo-pituitary-adrenal axis in the early post-operative period after hypophysectomy | Q48663250 | ||
| Mechanisms of impaired growth hormone secretion in genetically obese Zucker rats: roles of growth hormone-releasing factor and somatostatin | Q48854624 | ||
| Glucagon Stimulation of Human Growth Hormone | Q48906341 | ||
| Hypothalamic-pituitary-adrenal axis activity and its relationship to the autonomic nervous system in women with visceral and subcutaneous obesity: effects of the corticotropin-releasing factor/arginine-vasopressin test and of stress | Q49106251 | ||
| Free insulin-like growth factors in human obesity. | Q51585625 | ||
| Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-1 (IGFBP-1), IGFBP-3, and IGF-I in insulin-dependent diabetes. | Q51594172 | ||
| Hyperactivity of the hypothalamo-pituitary-adrenal axis in obesity: a study of ACTH, AVP, beta-lipotrophin and cortisol responses to insulin-induced hypoglycaemia. | Q51599309 | ||
| Hypoglycemia: a potent stimulus to secretion of growth hormone. | Q51692790 | ||
| Acute pharmacologic blockade of lipolysis normalizes nocturnal growth hormone levels and pulsatility in obese subjects. | Q52369747 | ||
| Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression. | Q52520837 | ||
| ACTH and cortisol response to combined corticotropin releasing hormone-arginine vasopressin stimulation in obese males and its relationship to body weight, fat distribution and parameters of the metabolic syndrome | Q57012723 | ||
| Glucagon is an ACTH secretagogue as effective as hCRH after intramuscolar administration while it is ineffective when given intravenously in normal subjects | Q60674318 | ||
| Intramuscular glucagon as a provocative stimulus for the assessment of pituitary function: growth hormone and cortisol responses | Q69075819 | ||
| Long-term administration of acipimox potentiates growth hormone response to growth hormone-releasing hormone by decreasing serum free fatty acid in obesity | Q71061272 | ||
| Glucagon-induced growth hormone release in children | Q71739579 | ||
| About the effects of glucagon on growth hormone release | Q71827899 | ||
| The assessment of growth hormone status in normal young adult males using a variety of provocative agents | Q71931824 | ||
| Repetitive GHRH administration fails to increase the response to GHRH in obese subjects. Evidence for a somatotrope defect in obesity? | Q72864600 | ||
| Low concentrations of insulin-like growth factor-I in abdominal obesity | Q72958838 | ||
| Interaction between glucagon and hexarelin, a peptidyl GH secretagogue, on somatotroph and corticotroph secretion in humans | Q73191651 | ||
| Comparisons among old and new provocative tests of GH secretion in 178 normal adults | Q73645023 | ||
| Interaction between glucagon and human corticotropin-releasing hormone or vasopressin on ACTH and cortisol secretion in humans | Q73931382 | ||
| Neuroendocrine abnormalities in visceral obesity | Q74345559 | ||
| The GH/IGF-I axis in obesity: influence of neuro-endocrine and metabolic factors | Q74345576 | ||
| Stimulatory effect of adrenocorticotropin on cortisol, aldosterone, and dehydroepiandrosterone secretion in normal humans: dose-response study | Q74352487 | ||
| Altered neuroregulation of GH secretion in viscerally obese premenopausal women | Q77148837 | ||
| Growth hormone in obesity | Q77292368 | ||
| Comparison of the diagnostic utility of the simplified and standard i.m. glucagon stimulation test (IMGST) | Q77344437 | ||
| Relationships between dehydroepiandrosterone-sulphate and anthropometric, metabolic and hormonal variables in a large cohort of obese women | Q78196746 | ||
| Growth Hormone Response to Intramuscular Glucagon | Q93756256 | ||
| P433 | issue | 6 | |
| P921 | main subject | obesity | Q12174 |
| glucagon | Q28163629 | ||
| P304 | page(s) | 551-556 | |
| P577 | publication date | 2002-06-01 | |
| P1433 | published in | Journal of Endocrinological Investigation | Q15766847 |
| P1476 | title | Glucagon administration elicits blunted GH but exaggerated ACTH response in obesity | |
| P478 | volume | 25 |
| Q38346795 | Obese patients with obstructive sleep apnoea syndrome show a peculiar alteration of the corticotroph but not of the thyrotroph and lactotroph function |
| Q36395186 | Systemic and local ACTH produced during inflammatory states promotes osteochondrogenic mesenchymal cell differentiation contributing to the pathologic progression of calcified atherosclerosis |
Search more.